Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib alternating with regorafenib versus imatinib alone as first-line treatment for advanced GIST
NL-OMON56311Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Imatinib control with Alternating imatinib and regorafenib (2 arms). Primary endpoint: Objective tumour response. Started Nov 2016; status: recruiting.
02
Drugs
imatinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON56311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56311.